Genta Will Appeal FDA “Not Approvable” Action On Genasense
This article was originally published in The Pink Sheet Daily
Executive Summary
Company highlights supporting statements from medical experts in quest to overcome FDA’s position on valid CLL endpoints.
You may also be interested in...
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
Genta Returns To Old Territory With New Genasense Study
Genasense/chemotherapy combination will be tried in approximately 300 biomarker-targeted treatment naive melanoma patients.
Genta Appeals FDA’s Genasense “Not Approvable” Decision
Firm says oncologic deserves approval after demonstrating a complete response in patients with CML.